Please assess the completion status of the following clinical trial:

Trial Title: EXL01 in the Maintenance of Steroid-induced Clinical Response/Remission in Participants With Mild to Moderate Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~Must meet all of the following criteria at the start of the Induction Period:~* Male or female aged ≥18 years and \<75 years at the time of providing informed consent.~* A diagnosis of CD with ileal involvement for at least 3 months prior to Screening.~* A CDAI score \>180 and \<350.~* Part B only: Active mucosal inflammation.~Key Exclusion Criteria:~* Stricture with obstructive syndrome \<3 months prior to Screening.~* Stenosis making endoscopic access to the terminal ileum difficult.~* Received treatment with high dose corticosteroid (≥40 mg prednisone daily) for \>5 weeks within 3 months prior to Screening.~* Part B only: Received \>3 prior biologic treatments or JAK inhibitors for CD including infliximab, ustekinumab, vedolizumab, adalimumab, certolizumab, risankizumab, and upadacitinib.~* Major surgery or significant trauma ≤4 weeks prior to Screening.~* Small bowel resection \>1 m in total or clinical manifestations of short bowel syndrome.~* Current stoma (ileostomy or a colostomy) or had a stoma in the last 6 months or any other intraabdominal surgery within 3 months prior to Screening.~* Started or stopped immunosuppressive therapy (thiopurine, methotrexate, tacrolimus, or other classical immunosuppressant) within 3 months prior to Screening.~* Received faecal microbial transplant within 3 months prior to Screening.~* Systemic infection or other serious infection requiring systemic treatment within 30 days prior to Screening.~* Pregnant, breastfeeding, or expecting to conceive during the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Part A (Open-Label EXL01 Maintenance Therapy) (Type: EXPERIMENTAL): Oral EXL01 once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
- Part B (EXL01 Maintenance Therapy) (Type: EXPERIMENTAL): Oral EXL01 once daily for up to 24 weeks (after SoC corticosteroid induction therapy).
- Part B (Placebo Maintenance Therapy) (Type: PLACEBO_COMPARATOR): Oral EXL01 matched placebo once daily for up to 24 weeks (after SoC corticosteroid induction therapy).

Based on this trial design, predict the completion outcome and termination type (if applicable).